Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by San Gwann
Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne | Dermatology and Therapy
Abstract Acne pathogenesis is multifactorial, involving systemic factors including gut dysbiosis, hormones, and chronic inflammation. Probiotics, myoinositol, and plant-derived molecules may modulate acne by targeting these factors. The objective is to compare a synbiotic containing herbs against a myoinositol-based herbal supplement on how they influence acne, the gut microbiome, short chain fatty acids (SCFAs), and hormonal profiles.
LTE - LIGHTHOUSE PROPERTIES PLC - Dividend declaration and availability of scrip distribution circular - 25/03/2025
Dividend declaration and availability of scrip distribution circular LIGHTHOUSE PROPERTIES p.l.c. (Registered in Malta) (Registration number: C 100848) Share code: LTE ISIN: MU0461N00015 LEI: 549300UG27SWRF0X2U62 ("Lighthouse" or the "Company") THE ATTENTION OF SHAREHOLDERS IS DRAWN TO THE FACT THAT THE SCRIP DISTRIBUTION IS LIMITED TO A MAXIMUM OF 50% OF THE TOTAL VALUE OF THE FINAL DISTRIBUTION DECLARED BY LIGHTHOUSE.
LTE - LIGHTHOUSE PROPERTIES PLC - Dividend declaration and availability of scrip distribution circular - 16/08/2024
Dividend declaration and availability of scrip distribution circular LIGHTHOUSE PROPERTIES p.l.c. (Registered in Malta) (Registration number: C 100848) Share code: LTE ISIN: MU0461N00015 LEI: 549300UG27SWRF0X2U62 ("Lighthouse" or the "Company") DIVIDEND DECLARATION AND AVAILABILITY OF SCRIP DISTRIBUTION CIRCULAR Shareholders are advised that on Wednesday, 14 August 2024, it was announced that the Lighthouse board of directors (the "Board") has approved an interim dividend of 1,21660 EUR cents...
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Daniela Melchiorri1*, Sara Merlo2, Benjamin Micallef3, John-Joseph Borg4, 5 and František Dráfi6 1Department of Physiology and Pharmacology, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy 2Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, Faculty of Medicine, University of Catania, Italy 3Malta Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000, Malta, Malta 4Malta Medicines Authority Sir Temi...
The Randomised Controlled Trial at the Intersection of Research Ethics and Innovation - Pharmaceutical Medicine
Abstract The randomised controlled trial (RCT) has been considered for a long time as the gold standard for evidence generation to support regulatory decision making for medicines. The randomisation procedure involves an ethical dilemma since it means leaving the treatment choice to chance. Although currently contested, the ethical justification for the RCT that has gained widespread acceptance is the notion of ‘clinical equipoise’.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with San
Contact San, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack